CY1110683T1 - ANTI-EGFR ANTIBODIES - Google Patents

ANTI-EGFR ANTIBODIES

Info

Publication number
CY1110683T1
CY1110683T1 CY20101100346T CY101100346T CY1110683T1 CY 1110683 T1 CY1110683 T1 CY 1110683T1 CY 20101100346 T CY20101100346 T CY 20101100346T CY 101100346 T CY101100346 T CY 101100346T CY 1110683 T1 CY1110683 T1 CY 1110683T1
Authority
CY
Cyprus
Prior art keywords
egfr
egfr antibodies
antigen
binding fragments
antibodies
Prior art date
Application number
CY20101100346T
Other languages
Greek (el)
Inventor
Catherine Brautigam Beidler
Alain Philippe Vasserot
Jeffry Dean Watkins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06837044A external-priority patent/EP1951759B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1110683T1 publication Critical patent/CY1110683T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση περικλείει ειδικά ως προς τον EGFR μονοκλωνικά αντισώματα ή τμήματα τους που προσδένουν αντιγόνο. Αυτά τα αντισώματα, ή τα τμήματα τους που προσδένουν αντιγόνο έχουν υψηλή συγγένεια για τον EGFR, αναστέλλουν την ενεργοποίηση του EGFR και είναι χρήσιμα για τη θεραπεία των καρκίνων που διαμεσολαβούνται από τον EGFR.The present invention encompasses EGFR-specific monoclonal antibodies or antigen-binding fragments thereof. These antibodies, or their antigen-binding fragments, are highly related to EGFR, inhibit EGFR activation, and are useful in the treatment of EGFR-mediated cancers.

CY20101100346T 2005-11-12 2010-04-16 ANTI-EGFR ANTIBODIES CY1110683T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73536305P 2005-11-12 2005-11-12
EP06837044A EP1951759B1 (en) 2005-11-12 2006-11-06 Anti-egfr antibodies

Publications (1)

Publication Number Publication Date
CY1110683T1 true CY1110683T1 (en) 2015-06-10

Family

ID=42664729

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100346T CY1110683T1 (en) 2005-11-12 2010-04-16 ANTI-EGFR ANTIBODIES

Country Status (1)

Country Link
CY (1) CY1110683T1 (en)

Similar Documents

Publication Publication Date Title
CY1125027T1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR THE TREATMENT OF CANCER
CY1116886T1 (en) C-MET ACCESSORIES
CY1123883T1 (en) HUMANIZED ANTIBODIES TO LIV-1 AND THEIR USE FOR THE THERAPEUTIC TREATMENT OF CANCER
CY1120412T1 (en) ILL-31 SPECIALIZED PARTICULAR PARTS
CY1115572T1 (en) CXCR4 ANTIBODIES AND USE OF THESE FOR CANCER TREATMENT
ATE461220T1 (en) ANTI-EGFR ANTIBODIES
CY1119591T1 (en) SPECIAL CONNECTION PROTEINS AND THEIR USES
CY1120065T1 (en) HUMAN ANTIBODIES FOR TON ERBB 2
CY1119454T1 (en) ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
CY1119794T1 (en) E-SELECTIN SUSPENSION UNITS
CY1124412T1 (en) ANTI-DKK-1 ANTIBODIES
CY1119956T1 (en) MONOCLONIC ANTI-GT468 CANCER TREATMENTS
CY1114658T1 (en) PRIMARY ANTIGEN COMMUNICATION Binding Proteins
MX2022014914A (en) Glycan-interacting compounds and methods of use.
CY1116167T1 (en) PHARMACEUTICAL COMPOSITIONS GUIDED ON ERB-B1
PH12019501773A1 (en) Anti-ccr7 antibody drug conjugates
CO6612264A2 (en) Therapeutic proteins of the binding to dll 4
CY1115321T1 (en) ANTIBODIES DIRECTED TO VASCULAR-1 AND VASCULAR-2 AND USE OF THESE
CY1118549T1 (en) USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMISTRY FOR TREATMENT OF BREAST CANCER
EA201791050A1 (en) CONJUGATES OF ANTIBODIES AND MEDICINES
DK2097453T3 (en) Monoclonal Antibodies to Human Anti-Müllerian Hormone Type II Receptor (AMHR-II)
CY1125102T1 (en) ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR
ATE526987T1 (en) DR5 ANTIBODIES AND THEIR USE
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
EA200701448A1 (en) SPECIFICALLY CONNECTED TO OUR MOBILE COURSE.